Person · CIK 1240122

Michael G Grey

Executive Chairman at OnKure Therapeutics, Mirum Pharmaceuticals and Spruce Biosciences

Earlier: Horizon Therapeutics, Biomarin Pharmaceutical, Mirati Therapeutics, Achillion Pharmaceuticals, Idm Pharma and SGX Pharmaceuticals

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$24.8M

Noticed on Form 144$12.4M

Bought on Form 4$95K

Companies9

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
OnKure Therapeutics RPHM	Common Stock	See footnote	134,084	Apr 13, 2021 · Filing · EDGAR
OnKure Therapeutics RPHM	Common Stock	By Trust	134,084	Jul 26, 2023 · Filing · EDGAR
OnKure Therapeutics RPHM	Stock Option (right to buy) exercise $4.14, expires Aug 6, 2036, into Class A Common Stock	Directly	22,350	Aug 7, 2026 · Filing · EDGAR
Mirum Pharmaceuticals MIRM	Common Stock	By The Grey Family Trust dated November 12, 1999	281,250	Jul 17, 2019 · Filing · EDGAR
Mirum Pharmaceuticals MIRM	Common Stock	By The Grey Family Trust dated November 12,1999	186,410	Dec 19, 2025 · Filing · EDGAR
Mirum Pharmaceuticals MIRM	Common Stock	By The Grey 2018 Irrevocable Children's Trust	93,750	Dec 19, 2025 · Filing · EDGAR
Mirum Pharmaceuticals MIRM	Stock Option (right to buy) exercise $101.00, expires Jun 14, 2036, into Common Stock	Directly	3,772	Jun 15, 2026 · Filing · EDGAR
Mirum Pharmaceuticals MIRM	Restricted Stock Units into Common Stock	Directly	1,980	Jun 15, 2026 · Filing · EDGAR
Spruce Biosciences SPRB	Stock Option (Right to Buy) exercise $52.70, expires May 20, 2036, into Common Stock	Directly	1,700	May 21, 2026 · Filing · EDGAR
Horizon Therapeutics	Ordinary Shares	By Trust	65,374	Apr 29, 2022 · Filing · EDGAR
Biomarin Pharmaceutical	Common Stock	Directly	42,840	Mar 5, 2021 · Filing · EDGAR
Mirati Therapeutics	Common Stock	Directly	5,731	Jan 15, 2021 · Filing · EDGAR
Mirati Therapeutics	Non Qualified Stock Option (right to buy) exercise $214.47, expires Jan 14, 2031, into Common Stock	Directly	2,155	Jan 15, 2021 · Filing · EDGAR
Idm Pharma	Restricted Stock Units into Common Stock	Directly	20,000	Dec 11, 2008 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)	Bought (Form 4)
Q4 2025	$11.1M	$11.1M	—
Q3 2023	$467K	$455K	—
Q2 2023	$833K	$833K	—
Q3 2021	$500K	Not machine-readable	—
Q2 2021	$1.4M	Not machine-readable	—
Q1 2021	$381K	Not machine-readable	—
Q4 2020	$2.7M	Not machine-readable	—
Q3 2020	$535K	Not machine-readable	—
Q2 2020	$610K	Not machine-readable	—
Q4 2019	$312K	Not machine-readable	—
Q3 2019	$281K	Not machine-readable	—
Q2 2019	$376K	Not machine-readable	—
Q2 2017	—	—	$95K
Q1 2016	$600K	Not machine-readable	—
Q4 2015	$782K	Not machine-readable	—
Q4 2013	$2.1M	Not machine-readable	—
Q1 2013	$909K	Not machine-readable	—
Q1 2008	$955K	Not machine-readable	—

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · 10b5-1 plan adopted Aug 22, 2025 · 3 notices
Dec 19, 2025	50,000 · ~$3.9M	Dec 19, 2025	Sold as noticed Sold 50,000 at $78.00 on Dec 19 · $3.9M Form 4	Filing · EDGAR
Dec 1, 2025	50,000 · ~$3.7M	Dec 1, 2025	Sold as noticed Sold 50,000 at $74.00 on Dec 1 · $3.7M Form 4	Filing · EDGAR
Nov 21, 2025	50,000 · ~$3.5M	Nov 21, 2025	Sold as noticed Sold 50,000 at $70.00 on Nov 21 · $3.5M Form 4	Filing · EDGAR
Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · 10b5-1 plan adopted Aug 30, 2022 · 2 notices
Sep 14, 2023	14,216 · ~$455K	Sep 14, 2023	Partly sold Sold 392 at $32.00 on Sep 13 · $13K likely match Form 4	Filing · EDGAR
May 3, 2023	14,608 · ~$409K	May 3, 2023	Sold as noticed Sold 14,608 at $28.00 on May 3 · $409K Form 4	Filing · EDGAR
Mirum Pharmaceuticals MIRM · E*Trade Financial · 10b5-1 plan adopted Aug 30, 2022 · 1 notice
Jun 8, 2023	14,608 · ~$424K	Jun 8, 2023	Sold as noticed Sold 14,608 at $29.00 on Jun 8 · $424K Form 4	Filing · EDGAR
Sales without a matching Form 144 · 66 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Sold without notice Mirum Pharmaceuticals (MIRM): Sold 14,216 at $32.00 on Sep 14, 2023 · $455K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Horizon Therapeutics: Sold 4,000 at $100.05 on Jul 22, 2021 · $400K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Horizon Therapeutics: Sold 1,000 at $100.00 on Jul 22, 2021 · $100K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Horizon Therapeutics: Sold 15,000 at $90.28 on Apr 12, 2021 · $1.4M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 5,000 at $76.28 on Mar 5, 2021 · $381K	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 89 at $249.42 on Dec 14, 2020 · $22K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 1,019 at $248.55 on Dec 14, 2020 · $253K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 1,997 at $247.62 on Dec 14, 2020 · $495K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 1,807 at $246.73 on Dec 14, 2020 · $446K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 1,284 at $245.11 on Dec 14, 2020 · $315K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 1,653 at $244.45 on Dec 14, 2020 · $404K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 1,815 at $243.35 on Dec 14, 2020 · $442K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 857 at $242.29 on Dec 14, 2020 · $208K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 379 at $241.22 on Dec 14, 2020 · $91K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Horizon Therapeutics: Sold 1,755 at $73.35 on Aug 5, 2020 · $129K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 2,500 at $120.35 on Aug 3, 2020 · $301K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Horizon Therapeutics: Sold 1,755 at $60.00 on Jul 22, 2020 · $105K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Horizon Therapeutics: Sold 1,755 at $55.00 on Jun 25, 2020 · $97K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Horizon Therapeutics: Sold 10,530 at $48.77 on May 22, 2020 · $514K	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 3,042 at $102.44 on Nov 12, 2019 · $312K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 260 at $93.98 on Aug 12, 2019 · $24K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 650 at $93.18 on Aug 12, 2019 · $61K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 1,100 at $92.34 on Aug 12, 2019 · $102K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 1,032 at $91.20 on Aug 12, 2019 · $94K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 300 at $66.08 on May 13, 2019 · $20K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Mirati Therapeutics: Sold 5,460 at $65.26 on May 13, 2019 · $356K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 7,500 at $80.00 on Feb 22, 2016 · $600K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 7,500 at $104.27 on Nov 16, 2015 · $782K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 30,000 at $69.66 on Dec 11, 2013 · $2.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 15,000 at $60.61 on Mar 6, 2013 · $909K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 200 at $38.45 on Mar 5, 2008 · $8K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 200 at $38.44 on Mar 5, 2008 · $8K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 100 at $38.43 on Mar 5, 2008 · $4K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 600 at $38.42 on Mar 5, 2008 · $23K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 1,400 at $38.41 on Mar 5, 2008 · $54K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 900 at $38.40 on Mar 5, 2008 · $35K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 100 at $38.39 on Mar 5, 2008 · $4K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 100 at $38.36 on Mar 5, 2008 · $4K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 500 at $38.35 on Mar 5, 2008 · $19K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 500 at $38.34 on Mar 5, 2008 · $19K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 700 at $38.33 on Mar 5, 2008 · $27K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 1,000 at $38.31 on Mar 5, 2008 · $38K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 300 at $38.30 on Mar 5, 2008 · $11K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 500 at $38.27 on Mar 5, 2008 · $19K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 200 at $38.26 on Mar 5, 2008 · $8K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 903 at $38.25 on Mar 5, 2008 · $35K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 600 at $38.24 on Mar 5, 2008 · $23K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 1,100 at $38.23 on Mar 5, 2008 · $42K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 600 at $38.22 on Mar 5, 2008 · $23K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 900 at $38.21 on Mar 5, 2008 · $34K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 900 at $38.20 on Mar 5, 2008 · $34K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 300 at $38.19 on Mar 5, 2008 · $11K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 443 at $38.18 on Mar 5, 2008 · $17K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 950 at $38.17 on Mar 5, 2008 · $36K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 1,700 at $38.16 on Mar 5, 2008 · $65K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 100 at $38.15 on Mar 5, 2008 · $4K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 1,100 at $38.14 on Mar 5, 2008 · $42K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 204 at $38.13 on Mar 5, 2008 · $8K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 1,900 at $38.11 on Mar 5, 2008 · $72K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 1,200 at $38.10 on Mar 5, 2008 · $46K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 100 at $38.08 on Mar 5, 2008 · $4K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 1,600 at $38.07 on Mar 5, 2008 · $61K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 1,000 at $38.06 on Mar 5, 2008 · $38K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 800 at $38.05 on Mar 5, 2008 · $30K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 500 at $38.04 on Mar 5, 2008 · $19K	Filing · EDGAR
—	—	—	Notice not machine-readable Biomarin Pharmaceutical: Sold 800 at $38.03 on Mar 5, 2008 · $30K	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

OnKure Therapeutics RPHM Executive Chairman · filings 2021 to 2026

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 7, 2026	Grant or award from the company Stock Option (right to buy)	+22,350			22,350 direct	Filing · EDGAR
Jun 4, 2026	Grant or award from the company Stock Option (right to buy)	+7,650			7,650 direct	Filing · EDGAR
May 28, 2025	Grant or award from the company Stock Option (right to buy)	+7,650			7,650 direct	Filing · EDGAR
Oct 4, 2024	Grant or award from the company Stock Option (right to buy)	+15,300			15,300 direct	Filing · EDGAR
Jul 26, 2023	Gift	−50,000			0 direct	Filing · EDGAR
Jun 6, 2023	Grant or award from the company Stock Option (right to buy)	+17,500			17,500 direct	Filing · EDGAR
Aug 31, 2022	Option or RSU exercised or converted	+50,000	$1.97	$99K	50,000 direct	Filing · EDGAR
Aug 31, 2022	Option or RSU exercised or converted Stock option (right to buy)	−50,000			67,406 direct	Filing · EDGAR
Jun 1, 2022	Grant or award from the company Stock Option (right to buy)	+17,500			17,500 direct	Filing · EDGAR
Apr 13, 2021	Derivative converted	+20,162			444,762 See footnote	Filing · EDGAR
Apr 13, 2021	Derivative converted Series A Preferred Stock	−90,222			0 See footnote	Filing · EDGAR
Apr 8, 2021	Grant or award from the company Stock Option (right to buy)	+14,000			14,000 direct	Filing · EDGAR

Mirum Pharmaceuticals MIRM Executive Chairman · filings 2019 to 2026 · sold $12.4M · $12.4M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 15, 2026	Grant or award from the company Stock Option (right to buy)	+3,772			3,772 direct	Filing · EDGAR
Jun 15, 2026	Grant or award from the company Restricted Stock Units	+1,980			1,980 direct	Filing · EDGAR
Dec 19, 2025	Option or RSU exercised or converted	+50,000	$2.94	$147K	50,000 direct	Filing · EDGAR
Dec 19, 2025	Sale under a 10b5-1 plan	−50,000	$78.00	$3.9M	0 direct	Filing · EDGAR
Dec 19, 2025	Option or RSU exercised or converted Stock Option (right to buy)	−50,000			181,176 direct	Filing · EDGAR
Dec 1, 2025	Option or RSU exercised or converted	+50,000	$2.94	$147K	50,000 direct	Filing · EDGAR
Dec 1, 2025	Sale under a 10b5-1 plan	−50,000	$74.00	$3.7M	0 direct	Filing · EDGAR
Dec 1, 2025	Option or RSU exercised or converted Stock Option (right to buy)	−50,000			231,176 direct	Filing · EDGAR
Nov 21, 2025	Option or RSU exercised or converted	+50,000	$2.94	$147K	50,000 direct	Filing · EDGAR
Nov 21, 2025	Sale under a 10b5-1 plan	−50,000	$70.00	$3.5M	0 direct	Filing · EDGAR
Nov 21, 2025	Option or RSU exercised or converted Stock Option (right to buy)	−50,000			281,176 direct	Filing · EDGAR
May 29, 2025	Grant or award from the company Stock Option (right to buy)	+6,268			6,268 direct	Filing · EDGAR
May 29, 2025	Grant or award from the company Deferred Stock Units	+3,977			3,977 direct	Filing · EDGAR
Sep 27, 2024	Gift	−102,788			186,410 By The Grey Family Trust dated November 12,1999	Filing · EDGAR
Jun 5, 2024	Grant or award from the company Stock Option (right to buy)	+8,779			8,779 direct	Filing · EDGAR
Jun 5, 2024	Grant or award from the company Deferred Stock Units	+5,703			5,703 direct	Filing · EDGAR
Sep 14, 2023	Option or RSU exercised or converted	+14,216	$2.94	$42K	14,216 direct	Filing · EDGAR
Sep 14, 2023	Sale under a 10b5-1 plan	−14,216	$32.00	$455K	0 direct	Filing · EDGAR
Sep 14, 2023	Option or RSU exercised or converted Stock Option (right to buy)	−14,216			331,176 direct	Filing · EDGAR
Sep 13, 2023	Option or RSU exercised or converted	+392	$2.94	$1K	392 direct	Filing · EDGAR
Sep 13, 2023	Sale under a 10b5-1 plan	−392	$32.00	$13K	0 direct	Filing · EDGAR
Sep 13, 2023	Option or RSU exercised or converted Stock Option (right to buy)	−392			345,392 direct	Filing · EDGAR
Jun 12, 2023	Grant or award from the company Stock Option (right to buy)	+17,000			17,000 direct	Filing · EDGAR
Jun 8, 2023	Option or RSU exercised or converted	+14,608	$2.94	$43K	14,608 direct	Filing · EDGAR
Jun 8, 2023	Sale under a 10b5-1 plan	−14,608	$29.00	$424K	0 direct	Filing · EDGAR
Jun 8, 2023	Option or RSU exercised or converted Stock Option (right to buy)	−14,608			345,784 direct	Filing · EDGAR
May 3, 2023	Option or RSU exercised or converted	+14,608	$2.94	$43K	14,608 direct	Filing · EDGAR
May 3, 2023	Sale under a 10b5-1 plan	−14,608	$28.00	$409K	0 direct	Filing · EDGAR
May 3, 2023	Option or RSU exercised or converted Stock Option (right to buy)	−14,608			360,392 direct	Filing · EDGAR
Jun 2, 2022	Grant or award from the company Stock Option (right to buy)	+17,000			17,000 direct	Filing · EDGAR
Jun 4, 2021	Grant or award from the company Stock Option (right to buy)	+17,000			17,000 direct	Filing · EDGAR
Jun 11, 2020	Grant or award from the company Stock Option (right to buy)	+17,000			17,000 direct	Filing · EDGAR
Jan 1, 2020	Grant or award from the company Stock Option (right to buy)	+100,000			100,000 direct	Filing · EDGAR
Jul 22, 2019	Derivative converted	+7,948			289,198 By The Grey Family Trust dated November 12,1999	Filing · EDGAR
Jul 22, 2019	Derivative converted Series A Prefered Stock	−63,585			0 By The Grey Family Trust dated November 12,1999	Filing · EDGAR

Spruce Biosciences SPRB Executive Chairman · filings 2020 to 2026

Date	Transaction	Shares	Held after	Source
May 21, 2026	Grant or award from the company Stock Option (Right to Buy)	+1,700	1,700 direct	Filing · EDGAR
Dec 11, 2025	Grant or award from the company Stock Option (Right to Buy)	+387	387 direct	Filing · EDGAR
Dec 11, 2025	Returned to the company Stock Option (Right to Buy)	−387	0 direct	Filing · EDGAR
Dec 11, 2025	Grant or award from the company Stock Option (Right to Buy)	+1,255	1,255 direct	Filing · EDGAR
Dec 11, 2025	Returned to the company Stock Option (Right to Buy)	−1,255	0 direct	Filing · EDGAR
Dec 11, 2025	Grant or award from the company Stock Option (Right to Buy)	+1,499	1,499 direct	Filing · EDGAR
Dec 11, 2025	Returned to the company Stock Option (Right to Buy)	−1,499	0 direct	Filing · EDGAR
Dec 11, 2025	Grant or award from the company Stock Option (right to buy)	+133	133 direct	Filing · EDGAR
Dec 11, 2025	Returned to the company Stock Option (right to buy)	−133	0 direct	Filing · EDGAR
Dec 11, 2025	Grant or award from the company Stock Option (Right to Buy)	+666	666 direct	Filing · EDGAR
Dec 11, 2025	Returned to the company Stock Option (Right to Buy)	−666	0 direct	Filing · EDGAR
Dec 11, 2025	Grant or award from the company Stock Option (Right to Buy)	+400	400 direct	Filing · EDGAR
Dec 11, 2025	Returned to the company Stock Option (Right to Buy)	−400	0 direct	Filing · EDGAR
Jul 22, 2025	Grant or award from the company Stock Option (Right to Buy)	+30,000	30,000 direct	Filing · EDGAR
May 22, 2024	Grant or award from the company Stock Option (Right to Buy)	+30,000	30,000 direct	Filing · EDGAR
May 25, 2023	Grant or award from the company Stock Option (Right to Buy)	+30,000	30,000 direct	Filing · EDGAR
May 25, 2022	Grant or award from the company Stock Option (Right to Buy)	+22,500	22,500 direct	Filing · EDGAR
Dec 16, 2021	Grant or award from the company Employee Stock Option (right to buy)	+50,000	50,000 direct	Filing · EDGAR
May 20, 2021	Grant or award from the company Stock Option (Right to Buy)	+10,000	10,000 direct	Filing · EDGAR

Horizon Therapeutics Director · filings 2011 to 2023 · sold $2.7M · bought $95K

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 6, 2023	Returned to the company	−39,361	$116.50	$4.6M	0 direct	Filing · EDGAR
Oct 6, 2023	Returned to the company	−48,031	$116.50	$5.6M	0 By Davy Trust	Filing · EDGAR
Oct 6, 2023	Returned to the company	−10,000	$116.50	$1.2M	0 By Family Trust	Filing · EDGAR
Oct 6, 2023	Returned to the company Stock Option (Right to Buy)	−8,548			0 direct	Filing · EDGAR
Oct 6, 2023	Returned to the company Stock Option (Right to Buy)	−23,092			0 direct	Filing · EDGAR
Oct 6, 2023	Returned to the company Stock Option (Right to Buy)	−31,153			0 direct	Filing · EDGAR
Oct 6, 2023	Returned to the company Stock Option (Right to Buy)	−32,161			0 direct	Filing · EDGAR
Oct 6, 2023	Returned to the company Restricted Stock Units	−4,016			0 direct	Filing · EDGAR
Sep 28, 2023	Option or RSU exercised or converted	+20,000	$15.96	$319K	39,361 direct	Filing · EDGAR
Sep 28, 2023	Option or RSU exercised or converted Stock Option (right to buy)	−20,000			0 direct	Filing · EDGAR
Jul 27, 2023	Grant or award from the company Restricted Stock Units	+4,016			4,016 direct	Filing · EDGAR
Apr 28, 2023	Option or RSU exercised or converted	+3,913			19,361 direct	Filing · EDGAR
Apr 28, 2023	Option or RSU exercised or converted Restricted Stock Units	−3,913			0 direct	Filing · EDGAR
Apr 29, 2022	Option or RSU exercised or converted	+4,223			66,513 By Trust	Filing · EDGAR
Apr 29, 2022	Shares withheld for tax or exercise price	−1,139	$98.56	$112K	65,374 By Trust	Filing · EDGAR
Apr 29, 2022	Option or RSU exercised or converted Restricted Stock Units	−4,223			0 direct	Filing · EDGAR
Apr 28, 2022	Grant or award from the company Restricted Stock Units	+3,913			3,913 direct	Filing · EDGAR
Jul 22, 2021	Option or RSU exercised or converted	+5,000	$2.37	$12K	5,000 direct	Filing · EDGAR
Jul 22, 2021	Sale under a 10b5-1 plan	−1,000	$100.00	$100K	4,000 direct	Filing · EDGAR
Jul 22, 2021	Sale under a 10b5-1 plan	−4,000	$100.05	$400K	0 direct	Filing · EDGAR
Jul 22, 2021	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			0 direct	Filing · EDGAR
Apr 30, 2021	Option or RSU exercised or converted	+11,098			73,388 By Trust	Filing · EDGAR
Apr 30, 2021	Shares withheld for tax or exercise price	−2,993	$94.62	$283K	70,395 By Trust	Filing · EDGAR
Apr 30, 2021	Option or RSU exercised or converted Restricted Stock Units	−11,098			0 direct	Filing · EDGAR
Apr 29, 2021	Grant or award from the company Restricted Stock Units	+4,223			4,223 direct	Filing · EDGAR
Apr 12, 2021	Option or RSU exercised or converted	+15,000	$2.37	$36K	15,000 direct	Filing · EDGAR
Apr 12, 2021	Sale under a 10b5-1 plan	−15,000	$90.28	$1.4M	0 direct	Filing · EDGAR
Apr 12, 2021	Option or RSU exercised or converted Stock Option (Right to Buy)	−15,000			5,000 direct	Filing · EDGAR
Aug 5, 2020	Option or RSU exercised or converted	+1,755	$3.95	$7K	1,755 direct	Filing · EDGAR
Aug 5, 2020	Sale under a 10b5-1 plan	−1,755	$73.35	$129K	0 direct	Filing · EDGAR
Aug 5, 2020	Option or RSU exercised or converted Stock Option (Right to Buy)	−1,755			0 direct	Filing · EDGAR
Jul 22, 2020	Option or RSU exercised or converted	+1,755	$3.95	$7K	1,755 direct	Filing · EDGAR
Jul 22, 2020	Sale under a 10b5-1 plan	−1,755	$60.00	$105K	0 direct	Filing · EDGAR
Jul 22, 2020	Option or RSU exercised or converted Stock Option (Right to Buy)	−1,755			1,755 direct	Filing · EDGAR
Jun 25, 2020	Option or RSU exercised or converted	+1,755	$3.95	$7K	1,755 direct	Filing · EDGAR
Jun 25, 2020	Sale under a 10b5-1 plan	−1,755	$55.00	$97K	0 direct	Filing · EDGAR
Jun 25, 2020	Option or RSU exercised or converted Stock Option (Right to Buy)	−1,755			3,510 direct	Filing · EDGAR
May 22, 2020	Option or RSU exercised or converted	+10,530	$7.84	$83K	10,530 direct	Filing · EDGAR
May 22, 2020	Open-market or private sale	−10,530	$48.77	$514K	0 direct	Filing · EDGAR
May 22, 2020	Option or RSU exercised or converted Stock Option (Right to Buy)	−10,530			0 direct	Filing · EDGAR
May 2, 2020	Option or RSU exercised or converted	+15,390			62,290 By Trust	Filing · EDGAR
May 2, 2020	Option or RSU exercised or converted Restricted Stock Units	−15,390			0 direct	Filing · EDGAR
Apr 30, 2020	Grant or award from the company Restricted Stock Units	+11,098			11,098 direct	Filing · EDGAR
May 3, 2019	Option or RSU exercised or converted	+15,320			51,032 By Trust	Filing · EDGAR
May 3, 2019	Shares withheld for tax or exercise price	−4,132	$26.54	$110K	46,900 By Trust	Filing · EDGAR
May 3, 2019	Option or RSU exercised or converted Restricted Stock Units	−15,320			0 direct	Filing · EDGAR
May 2, 2019	Grant or award from the company Restricted Stock Units	+15,390			15,390 direct	Filing · EDGAR
May 3, 2018	Option or RSU exercised or converted	+14,054			39,502 By Trust	Filing · EDGAR
May 3, 2018	Shares withheld for tax or exercise price	−3,790	$13.87	$53K	35,712 By Trust	Filing · EDGAR
May 3, 2018	Option or RSU exercised or converted Restricted Stock Units	−14,054			0 direct	Filing · EDGAR
May 3, 2018	Grant or award from the company Stock Option (Right to Buy)	+32,161			32,161 direct	Filing · EDGAR
May 3, 2018	Grant or award from the company Restricted Stock Units	+15,320			15,320 direct	Filing · EDGAR
May 10, 2017	Open-market or private purchase	+10,000	$9.48	$95K	25,448 By Trust	Filing · EDGAR
May 3, 2017	Option or RSU exercised or converted	+13,953			19,211 By Trust	Filing · EDGAR
May 3, 2017	Shares withheld for tax or exercise price	−3,763	$15.12	$57K	15,448 By Trust	Filing · EDGAR
May 3, 2017	Option or RSU exercised or converted Restricted Stock Units	−13,953			0 direct	Filing · EDGAR
May 3, 2017	Grant or award from the company Stock Option (Right to Buy)	+31,153			31,153 direct	Filing · EDGAR
May 3, 2017	Grant or award from the company Restricted Stock Units	+14,054			14,054 direct	Filing · EDGAR
May 6, 2016	Option or RSU exercised or converted	+5,258			5,258 By Trust	Filing · EDGAR
May 6, 2016	Option or RSU exercised or converted Restricted Stock Units	−5,258			0 direct	Filing · EDGAR

16 earlier transactions are in the filing list below.

Biomarin Pharmaceutical Director · filings 2005 to 2021 · sold $6M

Date	Transaction	Shares	Price	Value	Held after	Source
Mar 5, 2021	Option or RSU exercised or converted	+5,000	$26.49	$132K	47,840 direct	Filing · EDGAR
Mar 5, 2021	Open-market or private sale	−5,000	$76.28	$381K	42,840 direct	Filing · EDGAR
Mar 5, 2021	Option or RSU exercised or converted Stock Option (Right to buy Common Stock)	−5,000			0 direct	Filing · EDGAR
Aug 3, 2020	Option or RSU exercised or converted	+2,500	$26.49	$66K	45,340 direct	Filing · EDGAR
Aug 3, 2020	Sale under a 10b5-1 plan	−2,500	$120.35	$301K	42,840 direct	Filing · EDGAR
Aug 3, 2020	Option or RSU exercised or converted Stock Option (Right to buy Common Stock)	−2,500			5,000 direct	Filing · EDGAR
May 27, 2020	Grant or award from the company	+4,300			42,840 direct	Filing · EDGAR
Jun 4, 2019	Grant or award from the company	+4,430			38,540 direct	Filing · EDGAR
Jun 5, 2018	Grant or award from the company	+4,300			34,110 direct	Filing · EDGAR
Jun 6, 2017	Grant or award from the company	+2,050			29,810 direct	Filing · EDGAR
Jun 6, 2017	Grant or award from the company Stock Option (right to buy) Common Stock	+4,910			4,910 direct	Filing · EDGAR
Jun 6, 2016	Grant or award from the company	+1,510			27,760 direct	Filing · EDGAR
Jun 6, 2016	Grant or award from the company Stock Option (right to buy) Common Stock	+4,440			4,440 direct	Filing · EDGAR
Feb 22, 2016	Option or RSU exercised or converted	+7,500	$38.59	$289K	33,750 direct	Filing · EDGAR
Feb 22, 2016	Sale under a 10b5-1 plan	−7,500	$80.00	$600K	26,250 direct	Filing · EDGAR
Feb 22, 2016	Option or RSU exercised or converted Stock Option (right to buy) Common Stock	−7,500			0 direct	Filing · EDGAR
Nov 16, 2015	Option or RSU exercised or converted	+7,500	$38.59	$289K	33,750 direct	Filing · EDGAR
Nov 16, 2015	Sale under a 10b5-1 plan	−7,500	$104.27	$782K	26,250 direct	Filing · EDGAR
Nov 16, 2015	Option or RSU exercised or converted Stock Option (right to buy) Common Stock	−7,500			7,500 direct	Filing · EDGAR
Jun 10, 2015	Grant or award from the company	+1,100			26,250 direct	Filing · EDGAR
Jun 10, 2015	Grant or award from the company Stock Option (right to buy) common stock	+3,300			3,300 direct	Filing · EDGAR
Jun 6, 2014	Grant or award from the company	+2,100			25,150 direct	Filing · EDGAR
Jun 4, 2014	Grant or award from the company Stock Option (right to buy) common stock	+6,600			6,600 direct	Filing · EDGAR
Dec 11, 2013	Option or RSU exercised or converted	+7,500	$17.33	$130K	30,550 direct	Filing · EDGAR
Dec 11, 2013	Option or RSU exercised or converted	+15,000	$21.51	$323K	45,550 direct	Filing · EDGAR
Dec 11, 2013	Option or RSU exercised or converted	+7,500	$26.49	$199K	53,050 direct	Filing · EDGAR
Dec 11, 2013	Open-market or private sale	−30,000	$69.66	$2.1M	23,050 direct	Filing · EDGAR
Dec 11, 2013	Option or RSU exercised or converted Stock Option Right to Buy	−7,500			0 direct	Filing · EDGAR
Dec 11, 2013	Option or RSU exercised or converted Stock Option (right to buy)	−15,000			0 direct	Filing · EDGAR
Dec 11, 2013	Option or RSU exercised or converted Stock Option (right to buy)	−7,500			7,500 direct	Filing · EDGAR
May 15, 2013	Grant or award from the company	+3,400			23,050 direct	Filing · EDGAR
May 15, 2013	Grant or award from the company Stock Option (right to buy)	+8,500			8,500 direct	Filing · EDGAR
Mar 6, 2013	Open-market or private sale	−15,000	$60.61	$909K	19,650 direct	Filing · EDGAR
Mar 6, 2013	Option or RSU exercised or converted Stock Option (right to buy)	−15,000			0 direct	Filing · EDGAR
Mar 3, 2013	Option or RSU exercised or converted	+15,000	$14.39	$216K	34,650 direct	Filing · EDGAR
May 8, 2012	Grant or award from the company	+3,400			19,650 direct	Filing · EDGAR
May 8, 2012	Grant or award from the company Stock Option (right to buy)	+8,500			76,000 direct	Filing · EDGAR
Feb 23, 2012	Option or RSU exercised or converted	+30,000	$16.92	$508K	46,250 direct	Filing · EDGAR
Feb 23, 2012	Returned to the company	+30,000	$35.36	$1.1M	16,250 direct	Filing · EDGAR
Feb 23, 2012	Option or RSU exercised or converted Stock Option (right to buy)	+30,000			67,500 direct	Filing · EDGAR
May 12, 2011	Grant or award from the company	+2,500			16,250 direct	Filing · EDGAR
May 12, 2011	Grant or award from the company Stock Option (right to buy)	+15,000			97,500 direct	Filing · EDGAR
May 12, 2010	Grant or award from the company	+2,500			13,750 direct	Filing · EDGAR
May 12, 2010	Grant or award from the company Stock Option (right to buy)	+15,000			82,500 direct	Filing · EDGAR
May 22, 2009	Grant or award from the company	+2,500			11,250 direct	Filing · EDGAR
May 22, 2009	Grant or award from the company Restricted Stock Unit	−2,500			0 direct	Filing · EDGAR
May 12, 2009	Grant or award from the company	+2,500			8,750 direct	Filing · EDGAR
May 12, 2009	Grant or award from the company Stock Option (right to buy)	+15,000			67,500 direct	Filing · EDGAR
Jul 7, 2008	Grant or award from the company	+1,250			6,250 direct	Filing · EDGAR
Jul 7, 2008	Grant or award from the company Restricted Stock Unit	−1,250			2,500 direct	Filing · EDGAR
May 22, 2008	Grant or award from the company Stock Option (right to buy)	+15,000			52,500 direct	Filing · EDGAR
May 22, 2008	Grant or award from the company Restricted Stock Units	+2,500			3,750 direct	Filing · EDGAR
Mar 5, 2008	Option or RSU exercised or converted	+30,000	$10.33	$310K	30,000 direct	Filing · EDGAR
Mar 5, 2008	Open-market or private sale	−800	$38.03	$30K	29,200 direct	Filing · EDGAR
Mar 5, 2008	Open-market or private sale	−500	$38.04	$19K	28,700 direct	Filing · EDGAR
Mar 5, 2008	Open-market or private sale	−800	$38.05	$30K	27,900 direct	Filing · EDGAR
Mar 5, 2008	Open-market or private sale	−1,000	$38.06	$38K	26,900 direct	Filing · EDGAR
Mar 5, 2008	Open-market or private sale	−1,600	$38.07	$61K	25,300 direct	Filing · EDGAR
Mar 5, 2008	Open-market or private sale	−100	$38.08	$4K	25,200 direct	Filing · EDGAR
Mar 5, 2008	Open-market or private sale	−1,200	$38.10	$46K	24,000 direct	Filing · EDGAR

34 earlier transactions are in the filing list below.

Mirati Therapeutics Director · filings 2014 to 2021 · sold $3.6M

Date	Transaction	Shares	Price	Value	Held after	Source
Jan 15, 2021	Grant or award from the company	+1,475			5,731 direct	Filing · EDGAR
Jan 15, 2021	Grant or award from the company Non Qualified Stock Option (right to buy)	+2,155			2,155 direct	Filing · EDGAR
Dec 14, 2020	Option or RSU exercised or converted	+10,900	$16.84	$184K	15,156 direct	Filing · EDGAR
Dec 14, 2020	Sale under a 10b5-1 plan	−379	$241.22	$91K	14,777 direct	Filing · EDGAR
Dec 14, 2020	Sale under a 10b5-1 plan	−857	$242.29	$208K	13,920 direct	Filing · EDGAR
Dec 14, 2020	Sale under a 10b5-1 plan	−1,815	$243.35	$442K	12,105 direct	Filing · EDGAR
Dec 14, 2020	Sale under a 10b5-1 plan	−1,653	$244.45	$404K	10,452 direct	Filing · EDGAR
Dec 14, 2020	Sale under a 10b5-1 plan	−1,284	$245.11	$315K	9,168 direct	Filing · EDGAR
Dec 14, 2020	Sale under a 10b5-1 plan	−1,807	$246.73	$446K	7,361 direct	Filing · EDGAR
Dec 14, 2020	Sale under a 10b5-1 plan	−1,997	$247.62	$495K	5,364 direct	Filing · EDGAR
Dec 14, 2020	Sale under a 10b5-1 plan	−1,019	$248.55	$253K	4,345 direct	Filing · EDGAR
Dec 14, 2020	Sale under a 10b5-1 plan	−89	$249.42	$22K	4,256 direct	Filing · EDGAR
Dec 14, 2020	Option or RSU exercised or converted Non Qualified Stock Option (right to buy)	−10,900			0 direct	Filing · EDGAR
Jan 3, 2020	Grant or award from the company	+2,000			4,256 direct	Filing · EDGAR
Jan 3, 2020	Grant or award from the company Non Qualified Stock Option (right to buy)	+4,000			4,000 direct	Filing · EDGAR
Nov 12, 2019	Option or RSU exercised or converted	+3,500	$16.84	$59K	5,298 direct	Filing · EDGAR
Nov 12, 2019	Sale under a 10b5-1 plan	−3,042	$102.44	$312K	2,256 direct	Filing · EDGAR
Nov 12, 2019	Option or RSU exercised or converted Non-Qualified Stock Option (Right to Buy)	−3,500			10,900 direct	Filing · EDGAR
Aug 12, 2019	Option or RSU exercised or converted	+3,500	$16.84	$59K	4,840 direct	Filing · EDGAR
Aug 12, 2019	Sale under a 10b5-1 plan	−1,032	$91.20	$94K	3,808 direct	Filing · EDGAR
Aug 12, 2019	Sale under a 10b5-1 plan	−1,100	$92.34	$102K	2,708 direct	Filing · EDGAR
Aug 12, 2019	Sale under a 10b5-1 plan	−650	$93.18	$61K	2,058 direct	Filing · EDGAR
Aug 12, 2019	Sale under a 10b5-1 plan	−260	$93.98	$24K	1,798 direct	Filing · EDGAR
Aug 12, 2019	Option or RSU exercised or converted Non-Qualified Stock Option (Right to Buy)	−3,500			14,400 direct	Filing · EDGAR
May 13, 2019	Option or RSU exercised or converted	+7,100	$16.84	$120K	7,100 direct	Filing · EDGAR
May 13, 2019	Sale under a 10b5-1 plan	−5,460	$65.26	$356K	1,640 direct	Filing · EDGAR
May 13, 2019	Sale under a 10b5-1 plan	−300	$66.08	$20K	1,340 direct	Filing · EDGAR
May 13, 2019	Option or RSU exercised or converted Non-Qualified Stock Option (Right to Buy)	−7,100			17,900 direct	Filing · EDGAR
Jan 17, 2019	Grant or award from the company Non-Qualified Stock Option (right to buy)	+11,000			11,000 direct	Filing · EDGAR
Jan 18, 2018	Grant or award from the company Non-Qualified Stock Option (right to buy)	+10,000			10,000 direct	Filing · EDGAR
May 17, 2017	Grant or award from the company Non-Qualified Stock Option (right to buy)	+10,000			10,000 direct	Filing · EDGAR
May 18, 2016	Grant or award from the company Option Grant (Right to Buy)	+10,000			10,000 direct	Filing · EDGAR
May 21, 2015	Grant or award from the company Option Grant (Right to Buy)	+15,000			15,000 direct	Filing · EDGAR
Nov 5, 2014	Grant or award from the company Stock Option (Right to Buy)	+25,000			25,000 direct	Filing · EDGAR

Achillion Pharmaceuticals Director · filings 2006 to 2009

Date	Transaction	Shares	Held after	Source
Dec 18, 2009	Grant or award from the company Stock Option (Right to Buy)	+20,000	20,000 direct	Filing · EDGAR
Dec 15, 2008	Grant or award from the company Stock Option (Right to Buy)	+20,000	20,000 direct	Filing · EDGAR
Aug 18, 2008	Grant or award from the company Non Qualified Stock Option (Right to Buy)	+10,000	10,000 direct	Filing · EDGAR
Dec 14, 2007	Grant or award from the company Stock Option (Right to Buy)	+15,000	15,000 direct	Filing · EDGAR
Dec 19, 2006	Grant or award from the company Stock Option (Right to Buy)	+15,000	15,000 direct	Filing · EDGAR

Idm Pharma Director · filings 2003 to 2008

Date	Transaction	Shares	Held after	Source
Dec 11, 2008	Grant or award from the company Restricted Stock Units	+20,000	20,000 direct	Filing · EDGAR
Jun 25, 2008	Grant or award from the company Non-qualified stock option	+10,000	10,000 direct	Filing · EDGAR
Jan 10, 2008	Grant or award from the company Restricted Stock Units	+20,000	20,000 direct	Filing · EDGAR
Jun 14, 2007	Grant or award from the company Non-qualified stock option (right to buy)	+5,000	5,000 direct	Filing · EDGAR
Jun 14, 2006	Grant or award from the company Non-qualified stock option (right to buy)	+5,000	5,000 direct	Filing · EDGAR
Sep 16, 2005	Grant or award from the company Non-Qualified Stock Option	+17,143	17,143 direct	Filing · EDGAR
Aug 16, 2005	Grant or award from the company Non-Qualified Stock Option	+2,857	2,857 direct	Filing · EDGAR
Jun 15, 2004	Grant or award from the company Non-Qualified Stock Option	+5,000	5,000 direct	Filing · EDGAR

SGX Pharmaceuticals President & CEO · filings 2006 to 2008

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 20, 2008	Returned to the company	−100,000	$3.00	$300K	0 by Trust	Filing · EDGAR
Aug 20, 2008	Returned to the company Incentive Stock Option (right to buy)	−263,863	$2.00	$528K	0 direct	Filing · EDGAR
Aug 20, 2008	Returned to the company Incentive Stock Option (right to buy)	−52,893			0 direct	Filing · EDGAR
Aug 20, 2008	Returned to the company Incentive Stock Option (right to buy)	−2,383			0 direct	Filing · EDGAR
Aug 20, 2008	Returned to the company Incentive Stock Option (right to buy)	−27,761			0 direct	Filing · EDGAR
Aug 20, 2008	Returned to the company Incentive Stock Option (right to buy)	−26,228			0 direct	Filing · EDGAR
Aug 20, 2008	Returned to the company Incentive Stock Option (right to buy)	−5,058			0 direct	Filing · EDGAR
Aug 20, 2008	Returned to the company Non-Qualified Stock Option (right to buy)	−97,107			0 direct	Filing · EDGAR
Aug 20, 2008	Returned to the company Non-Qualified Stock Option (right to buy)	−105,239			0 direct	Filing · EDGAR
Aug 20, 2008	Returned to the company Non-Qualified Stock Option (right to buy)	−53,772			0 direct	Filing · EDGAR
Feb 21, 2008	Grant or award from the company Incentive Stock Option (right to buy)	+27,761			27,761 direct	Filing · EDGAR
Feb 21, 2008	Grant or award from the company Non-Qualified Stock Option (right to buy)	+105,239			105,239 direct	Filing · EDGAR
Jan 26, 2007	Grant or award from the company Incentive Stock Option (right to buy)	+52,893			52,893 direct	Filing · EDGAR
Jan 26, 2007	Grant or award from the company Non-Qualified Stock Option (right to buy)	+97,107			97,107 direct	Filing · EDGAR
Mar 7, 2006	Grant or award from the company Employee Stock Option (Right to Buy)	+80,000			80,000 direct	Filing · EDGAR

All 134 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Aug 11, 2026	Form 4	OnKure Therapeutics RPHM	Filing · EDGAR
Jun 17, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 8, 2026	Form 4	OnKure Therapeutics RPHM	Filing · EDGAR
May 26, 2026	Form 4	Spruce Biosciences SPRB	Filing · EDGAR
Dec 23, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Dec 19, 2025	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Dec 15, 2025	Form 4	Spruce Biosciences SPRB	Filing · EDGAR
Dec 2, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Dec 1, 2025	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Nov 25, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Nov 21, 2025	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jul 24, 2025	Form 4	Spruce Biosciences SPRB	Filing · EDGAR
Jun 2, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
May 30, 2025	Form 4	OnKure Therapeutics RPHM	Filing · EDGAR
Oct 8, 2024	Form 4	OnKure Therapeutics RPHM	Filing · EDGAR
Oct 1, 2024	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 7, 2024	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
May 24, 2024	Form 4	Spruce Biosciences SPRB	Filing · EDGAR
Oct 6, 2023	Form 4	Horizon Therapeutics	Filing · EDGAR
Sep 28, 2023	Form 4	Horizon Therapeutics	Filing · EDGAR
Sep 14, 2023	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Sep 14, 2023	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jul 28, 2023	Form 4	Horizon Therapeutics	Filing · EDGAR
Jul 27, 2023	Form 4	OnKure Therapeutics RPHM	Filing · EDGAR
Jun 14, 2023	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 9, 2023	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 8, 2023	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 8, 2023	Form 4	OnKure Therapeutics RPHM	Filing · EDGAR
May 26, 2023	Form 4	Spruce Biosciences SPRB	Filing · EDGAR
May 4, 2023	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
May 3, 2023	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
May 2, 2023	Form 4	Horizon Therapeutics	Filing · EDGAR
Sep 2, 2022	Form 4	OnKure Therapeutics RPHM	Filing · EDGAR
Jun 6, 2022	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 3, 2022	Form 4	OnKure Therapeutics RPHM	Filing · EDGAR
May 27, 2022	Form 4	Spruce Biosciences SPRB	Filing · EDGAR
May 2, 2022	Form 4	Horizon Therapeutics	Filing · EDGAR
Dec 20, 2021	Form 4	Spruce Biosciences SPRB	Filing · EDGAR
Jul 23, 2021	Form 4	Horizon Therapeutics	Filing · EDGAR
Jun 8, 2021	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
May 21, 2021	Form 4	Spruce Biosciences SPRB	Filing · EDGAR
Apr 30, 2021	Form 4	Horizon Therapeutics	Filing · EDGAR
Apr 15, 2021	Form 3/A	OnKure Therapeutics RPHM	Filing · EDGAR
Apr 15, 2021	Form 4	OnKure Therapeutics RPHM	Filing · EDGAR
Apr 13, 2021	Form 4	Horizon Therapeutics	Filing · EDGAR
Apr 12, 2021	Form 4	OnKure Therapeutics RPHM	Filing · EDGAR
Apr 8, 2021	Form 3	OnKure Therapeutics RPHM	Filing · EDGAR
Mar 9, 2021	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Jan 20, 2021	Form 4	Mirati Therapeutics	Filing · EDGAR
Dec 16, 2020	Form 4	Mirati Therapeutics	Filing · EDGAR
Oct 8, 2020	Form 3	Spruce Biosciences SPRB	Filing · EDGAR
Aug 7, 2020	Form 4	Horizon Therapeutics	Filing · EDGAR
Aug 5, 2020	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Jul 22, 2020	Form 4	Horizon Therapeutics	Filing · EDGAR
Jun 26, 2020	Form 4	Horizon Therapeutics	Filing · EDGAR
Jun 15, 2020	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
May 29, 2020	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
May 26, 2020	Form 4	Horizon Therapeutics	Filing · EDGAR
May 4, 2020	Form 4	Horizon Therapeutics	Filing · EDGAR
Jan 7, 2020	Form 4	Mirati Therapeutics	Filing · EDGAR
Jan 2, 2020	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Nov 14, 2019	Form 4	Mirati Therapeutics	Filing · EDGAR
Aug 14, 2019	Form 4	Mirati Therapeutics	Filing · EDGAR
Jul 24, 2019	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jul 17, 2019	Form 3	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 6, 2019	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
May 15, 2019	Form 4	Mirati Therapeutics	Filing · EDGAR
May 6, 2019	Form 4	Horizon Therapeutics	Filing · EDGAR
Jan 22, 2019	Form 4	Mirati Therapeutics	Filing · EDGAR
Jun 7, 2018	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
May 7, 2018	Form 4	Horizon Therapeutics	Filing · EDGAR
Jan 22, 2018	Form 4	Mirati Therapeutics	Filing · EDGAR
Jun 8, 2017	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
May 19, 2017	Form 4	Mirati Therapeutics	Filing · EDGAR
May 10, 2017	Form 4	Horizon Therapeutics	Filing · EDGAR
May 4, 2017	Form 4	Horizon Therapeutics	Filing · EDGAR
Jun 8, 2016	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
May 19, 2016	Form 4	Mirati Therapeutics	Filing · EDGAR
May 10, 2016	Form 4	Horizon Therapeutics	Filing · EDGAR
May 5, 2016	Form 4	Horizon Therapeutics	Filing · EDGAR
Feb 23, 2016	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Nov 18, 2015	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Jun 18, 2015	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
May 22, 2015	Form 4	Mirati Therapeutics	Filing · EDGAR
May 8, 2015	Form 4	Horizon Therapeutics	Filing · EDGAR
Nov 6, 2014	Form 4	Mirati Therapeutics	Filing · EDGAR
Nov 6, 2014	Form 3	Mirati Therapeutics	Filing · EDGAR
Sep 22, 2014	Form 4	Horizon Therapeutics	Filing · EDGAR
Sep 22, 2014	Form 3	Horizon Therapeutics	Filing · EDGAR
Sep 22, 2014	Form 4	Horizon Therapeutics	Filing · EDGAR
Jun 30, 2014	Form 4	Horizon Therapeutics	Filing · EDGAR
Jun 6, 2014	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Dec 13, 2013	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Jun 3, 2013	Form 4	Horizon Therapeutics	Filing · EDGAR
May 17, 2013	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Mar 8, 2013	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Feb 22, 2013	Form 4	Horizon Therapeutics	Filing · EDGAR
May 10, 2012	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Feb 24, 2012	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Oct 3, 2011	Form 3	Horizon Therapeutics	Filing · EDGAR
Oct 3, 2011	Form 4	Horizon Therapeutics	Filing · EDGAR
May 16, 2011	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
May 14, 2010	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Dec 22, 2009	Form 4	Achillion Pharmaceuticals	Filing · EDGAR
May 27, 2009	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
May 14, 2009	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Dec 17, 2008	Form 4	Achillion Pharmaceuticals	Filing · EDGAR
Dec 12, 2008	Form 4	Idm Pharma	Filing · EDGAR
Aug 21, 2008	Form 4	SGX Pharmaceuticals	Filing · EDGAR
Aug 20, 2008	Form 4	Achillion Pharmaceuticals	Filing · EDGAR
Jul 8, 2008	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Jun 25, 2008	Form 4	Idm Pharma	Filing · EDGAR
May 27, 2008	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Mar 7, 2008	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Mar 7, 2008	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Feb 25, 2008	Form 4	SGX Pharmaceuticals	Filing · EDGAR
Jan 15, 2008	Form 4	Idm Pharma	Filing · EDGAR
Dec 18, 2007	Form 4	Achillion Pharmaceuticals	Filing · EDGAR
Jun 18, 2007	Form 4	Idm Pharma	Filing · EDGAR
Jun 11, 2007	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Jan 29, 2007	Form 4	SGX Pharmaceuticals	Filing · EDGAR
Dec 26, 2006	Form 4	Achillion Pharmaceuticals	Filing · EDGAR
Dec 18, 2006	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Oct 25, 2006	Form 3	Achillion Pharmaceuticals	Filing · EDGAR
Jun 16, 2006	Form 4	Idm Pharma	Filing · EDGAR
Mar 9, 2006	Form 4	SGX Pharmaceuticals	Filing · EDGAR
Jan 31, 2006	Form 3	SGX Pharmaceuticals	Filing · EDGAR
Dec 21, 2005	Form 4	Biomarin Pharmaceutical	Filing · EDGAR
Dec 21, 2005	Form 3	Biomarin Pharmaceutical	Filing · EDGAR
Sep 19, 2005	Form 4	Idm Pharma	Filing · EDGAR
Aug 17, 2005	Form 4	Idm Pharma	Filing · EDGAR
Jun 15, 2004	Form 4	Idm Pharma	Filing · EDGAR
Jul 28, 2003	Form 4/A	Idm Pharma	Filing · EDGAR
Jul 18, 2003	Form 4	Idm Pharma	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 1:17 AM ET. The filing on SEC.gov is the record.